Management of Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis With Inhaled Fluticasone Propionate/Salmeterol (ADVAIR DISKUS) 250/50: Results of a Patient Experience Trial

類似資料

• Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
  著者:: Koser, Andras, 等
  出版事項: (2010)
• Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies
  著者:: Haughie, Scott, 等
  出版事項: (2020)
• Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects
  著者:: Kirjavainen, Merja, 等
  出版事項: (2018)
• Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease
  著者:: Vestbo, J, 等
  出版事項: (2005)
• Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
  著者:: Ohar, Jill A, 等
  出版事項: (2014)